Suven gets patent for Alzheimer's compound
This article was originally published in Scrip
The Indian biopharmaceutical company Suven Life Sciences has been granted patents on its clinical candidate (SUVN-502) for Alzheimer's disease in several countries. These include India, Mexico, South Africa, Singapore, New Zealand, Korea, Eurasia, Australia and Europe and the patent is valid till June 2023, the company informed the Bombay Stock Exchange. SUVN-502 is a potent, highly selective, brain penetrant and orally active antagonist at a non-peripheral CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition such as attention deficient hyperactivity, Parkinson's disease and schizophrenia. The compound has completed Phase I single-ascending and multiple-ascending studies in Switzerland and has demonstrated safety at all doses, with potential as a once-daily treatment. Phase II proof-of-concept studies are expected next year. Suven has also claimed that some companies have initiated the process of due diligence for potential partnerships for SUVN-502.
You may also be interested in...
Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, discusses in a wide-ranging interview the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.